Moxetumomab pasudotox: Anti-CD22 immunotoxin oncolytic

Research output: Contribution to journalArticlepeer-review


The development of recombinant immunotoxins as an alternative to conventional chemotherapy is promising, especially for the treatment of hematological malignancies. Protein toxins, such as Pseudomonas exotoxin (PE), are extremely potent and have significant systemic toxicity without targeting. When coupled to a CD22-targeted monoclonal antibody, the cytotoxicity of PE can be directed to the malignant CD22-positive B cells of leukemias and lymphomas. Moxetumomab pasudotox is a promising new therapy with significant activity in hairy cell leukemia (HCL) and acute lymphoblastic leukemia (ALL). Major toxicities have included elevated aminotransferases and hemolytic uremic syndrome. Additionally, many patients developed neutralizing antibodies, resulting in premature termination of treatment. Phase I/II trials in patients with relapsed/refractory HCL and ALL have generated encouraging results, with overall response rates of 86% and 30%, respectively. Early-phase trials are ongoing in patients with CLL and non-Hodgkin's lymphoma. Removal of B- and T-cell epitopes from PE has yielded analogues of moxetumomab pasudotox with superior activity, reduced nonspecific toxicity and reduced immunogenicity in preclinical models.

Original languageEnglish (US)
Pages (from-to)567-570
Number of pages4
JournalDrugs of the Future
Issue number8
StatePublished - 2012


  • Anti-CD22 immunotoxin
  • CAT-8015
  • Moxetumomab pasudotox
  • Pseudomonas exotoxin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Moxetumomab pasudotox: Anti-CD22 immunotoxin oncolytic'. Together they form a unique fingerprint.

Cite this